Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor

Diabetes, Obesity and Metabolism

Volumn 12, Issue 8, 2010, Pages 665-673

  Sorensen A R ^a   Stidsen, C E ^a   Ribel, U ^a   Nishimura, E ^a   Sturis, J ^a   Jonassen, I ^a   Bouman, S D ^a   Kurtzhals, P ^a   Brand, C L ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Glucose clamp; Insulin detemir; Lipogenesis; Receptor binding

Indexed keywords

ALBUMIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN RECEPTOR;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLISM; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 77958107768     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01206.x     Document Type: Article

References (23)

1. Markussen J, Andersen AS, Vad K. Synthesis of the soluble, long-acting insulin NN304. Diabetes 1996; 45: 805.
2. Schaffer L, Jonassen I, Markussen J et al. NN304-a new, soluble, longacting insulin analog. Diabetes 1996; 45: 508.
3. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, MarkussenJ. Albumin binding and time action of acylated insulins in various species. J Pharm Sci 1996; 85: 304-308.
4. Kurtzhals P, Havelund S, Jonassen I et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo.Biochem J 1995; 312: 725-731.
5. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res (Dordrecht) 2004; 21: 1498-1504.
6. Bock G, Wutte A, Koehler G, Korsatko S, Semlitsch B, Pieber TR. Pharmacodynamics and pharmacokinetics of long-acting insulin analogues detemir and glargine after 7 days of use and after its first administration in subjects with type 1 diabetes. Diabetologia 2008; 51: S390.
7. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9: 290-299.
8. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes. Clin Ther 2006; 28: 1569-1581.
9. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.
10. Neville DM. Isolation of an organ specific protein antigen from cell-surface membrane of rat liver. Biochem Biophys Acta 1968; 154: 540-552.
11. Moody AJ, Stan MA, Stan M, Gliemann J. A simple free fat cell bioassay for insulin. Horm Metab Res 1974; 6: 12-16.
12. Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 1964; 239: 375-380.
13. Somogyi M. Determination of blood sugar. J Biol Chem 1945; 160: 69-73.
14. Ferré P, Leturque A, Burnol AF, Penicaud L, Girard J. A method to quantify glucose utilization in vivo in skeletal muscle and white adipose tissue of the anaesthetized rat. Biochem J 1985; 228: 103-110.
15. Vølund A. Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models. Biometrics 1978; 34: 357-365.
16. Hamilton-Wessler M, Ader M, Dea M et al. Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 1999; 42: 1254-1263.
17. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T. Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract 2008; 81: 269-277.
18. Jonassen I, Havelund S, Ribel U et al. Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm Res 2005; 23: 49-55.
19. Markussen J, Havelund S, Kurtzhals P et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39: 281-288.
20. Hansen BF, Danielsen GM, Drejer K et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996; 315: 271-279.
21. Böhm A, Staiger H, Hennige AM, Haas C, Machicao F, Haring HU. Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis. Regul Pept 2008; 151: 160-163.
22. Brunner GA, Sendhofer G, Wutte A et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 2000; 108: 100-105.
23. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-1112.